NCT04488003: Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

NCT04488003
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MEK, BRAF
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details; Patients with prior therapy with any ERK inhibitor (e.g. LY3214996, LTT462).
https://ClinicalTrials.gov/show/NCT04488003

Comments are closed.

Up ↑